Human Interferon-α1 (hIFN-α1) #8927
We recommend the following alternatives
#
Product Name
Inquiry Info. # 8927
Please see our recommended alternatives.
Product Information
Formulation
Storage
Product Description
| MW (kDa) | 18 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIFN-α1. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1 μg hIFN-α1. |
| Activity | The bioactivity of hIFN-α1 was determined in a virus protection assay. The ED50 of each lot is between 0.01-1.0 ng/ml. |
| Molecular Formula | Recombinant hIFN-α1 does not have a Met on the amino terminus and has a calculated MW of 19,386. DTT-reduced protein migrates as an 18 kDa polypeptide and non-reduced protein migrates as a 14 kDa polypeptide due to intramolecular cystines. The expected amino-terminal CDLPE of recombinant hIFN-α1 was verified by amino acid sequencing. |
Source / Purification
Background
- Nagai, T. et al. (2003) J Immunol 171, 5233-43.
- Stetson, D.B. and Medzhitov, R. (2006) Immunity 25, 373-81.
- Vilcek, J. (2006) Immunity 25, 343-8.
- Luft, T. et al. (2002) Int Immunol 14, 367-80.
- van Boxel-Dezaire, A.H. et al. (2006) Immunity 25, 361-72.
- Banchereau, J. and Pascual, V. (2006) Immunity 25, 383-92.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.